You are here

Targeting ether lipid biosynthesis for disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA189390-01
Agency Tracking Number: R43CA189390
Amount: $224,334.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
675 Arapeen Drive, Suite 302
Salt Lake City, UT 84108-1228
United States
DUNS: 179151188
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (801) 588-0455
Business Contact
Phone: (801) 588-0455
Research Institution

DESCRIPTION (provided by applicant): Cancer is a significant health burden in the US and across the globe, representing the second leading cause of death in the US. Cancer cells have metabolic pathways that are altered significantly compared to normal cells. As a result, the pathways involved (lipid biosynthesis for example) are considered excellent targets for therapeutic intervention. The levels of ether lipids have been found elevated in cancer cells, but it was not until late 2013 that a specific role in cancer was described. Historically, these important signaling molecules were investigated in peroxisomal disorders, where decreased levels result in assorted diseases that often cause death before the age of twenty. The 2013 report revealed an importantrole for ether lipids in tumor cell growth. The precursor for all ethe lipids is produced in cells by the enzyme alkyldihydroxyacetone phosphate synthase (ADPS), also called alkylglycerone phosphate synthase (AGPS). The report mentioned above describe

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government